Mindfulness therapy is being studied as one possible part of care for people with opioid misuse and chronic pain. The recent cost-effectiveness findings around Mindfulness-Oriented Recovery Enhancement, known as MORE, are encouraging, but they should be read with care. These findings do not mean that meditation, breath awareness, or any group program should replace medical care, medication decisions, behavioral health support, or emergency help. Anyone dealing with opioid use concerns, chronic pain, withdrawal symptoms, medication questions, or safety risks should seek guidance from a qualified health professional.
Why Cost-Effectiveness Matters
Cost-effectiveness research asks a practical question: if a health program requires time, trained staff, and funding, what outcomes appear to come from that investment? For opioid misuse, this question is not only financial. It also touches access, clinical fit, insurance decisions, and whether patients can realistically attend sessions while managing pain, work, family duties, transportation, or other barriers.
Mindfulness-oriented programs are often discussed in wellness settings as low-risk skills for attention, emotion regulation, and stress awareness. In clinical research, however, the bar is higher. Researchers have to define who was studied, what comparison group was used, how outcomes were measured, and how long benefits were observed. That makes the recent MORE research useful, while still leaving room for caution.
Cost Is Not The Same As Clinical Fit
A program can look economically favorable in a study and still be unsuitable for a specific person. Needs may differ by medical history, mental health status, pain diagnosis, pregnancy, substance use history, medication plan, insurance coverage, and access to trained clinicians. Cost data can inform policy and program planning, but it cannot decide what care is appropriate for an individual.
For a more comprehensive understanding of the economic aspects related to interventions like these, exploring this internal review of MORE opioid misuse research could be beneficial. Additionally, those interested in broad health education topics may wish to consult resources from Trinity Bariatric Institute.
What Mindfulness Therapy Research Measured
The main clinical evidence behind the economic discussion came from a randomized clinical trial of 250 adults with chronic pain who were misusing prescribed opioids and receiving long-term opioid therapy. Enrollment ran from January 4, 2016, to January 16, 2020. Participants were assigned to either MORE or supportive group therapy, with 8 weekly 2-hour group sessions and follow-up through 9 months, according to the published trial report in the randomized clinical trial.
Mindfulness Therapy Versus Supportive Psychotherapy
In that trial, 45.0% of participants in the MORE group had ceased misusing opioids by 9 months, compared with 24.4% in the supportive psychotherapy control group. The study also reported greater reductions for MORE participants in opioid dose, pain severity, pain-related functional interference, emotional distress, and craving across the 9-month period.
Those findings are meaningful, but the comparison matters. MORE was not compared with doing nothing in a general wellness population. It was compared with an active supportive group therapy condition in adults who had chronic pain and opioid misuse while on long-term opioid therapy. For readers, mindfulness therapy in this context refers to a structured, research-tested group intervention, not simply using a meditation app or trying a breathing exercise during stress.
Economic Findings From MORE
A later economic analysis, published online on July 23, 2026, evaluated the same general intervention question through a cost-effectiveness lens. The analysis reported that, at 9-month follow-up, 54% of participants in the MORE group were still misusing opioids compared with 78% in the control group. That represented a difference in misuse probability of 0.24. The incremental cost-effectiveness ratio was reported as US$116 per averted case of opioid misuse.
A separate University of Utah Health report on the 2026 economic findings stated that MORE had a benefit-to-cost ratio of 12:1 and estimated lifetime cost savings of US$324,489 per patient in the analysis University of Utah Health report. Those figures suggest that the intervention may offer value when delivered in settings similar to those studied. They should not be read as a guaranteed savings estimate for every clinic, insurer, or patient group.
Reading The Numbers Carefully
Benefit-to-cost ratios depend on assumptions. They can be shaped by session costs, staffing models, patient retention, downstream medical expenses, and how long observed effects are expected to last. A favorable ratio is useful for discussion, but it is not the same as proof that every health system can reproduce the same result.
The 2026 research also sits within a wider evidence base that has mixed features. A 2026 systematic review described mindfulness-based interventions for opioid use disorder as promising adjunct approaches, with reductions in craving and physical pain and improvements in quality of life and emotional status across some trials. The same review noted high variation in methods and variable durability of effects. That caution is central: positive signals do not remove the need for replication, careful patient selection, trained delivery, and monitoring.
How Breathwork Fits Into The Discussion
As a mindfulness advocate, I often view breath awareness as a practical entry point because it is observable, brief, and can help a person notice stress physiology before reacting. In MORE, mindfulness practices are part of a broader structured intervention rather than a stand-alone breathing routine. That distinction keeps expectations grounded.
Breathwork may support awareness of tension, craving cues, or emotional discomfort for some people, but it should not be framed as a replacement for opioid use disorder care, pain management, medication-assisted care, mental health treatment, or clinician-directed safety planning. People taking prescribed opioids should not change dose, timing, or use patterns based on mindfulness content. Medication decisions need a qualified prescriber.
What The Research Does Not Prove
The research does not show that every mindfulness program reduces opioid misuse. It does not prove that a short daily practice produces the same results as an 8-session clinician-led group intervention. It also does not prove that economic savings will appear in every population. Differences in training, attendance, co-occurring mental health conditions, pain severity, and access to care may change outcomes.
This is why cautious interpretation matters. Mindfulness therapy may support some people as part of coordinated care, but the strongest claims apply to the studied intervention, population, and follow-up periods. A person’s care plan should be guided by clinicians who can assess pain, opioid use patterns, behavioral health needs, and safety.
Mindfulness Therapy for Opioid Misuse
The recent MORE findings give policymakers, clinicians, and researchers a stronger reason to study structured mindfulness-based care in opioid misuse settings. The economic findings are notable because they suggest possible value beyond symptom scores, including avoided misuse cases and projected savings. Still, the evidence calls for careful implementation rather than casual adoption.
If mindfulness therapy is being discussed as part of care, useful questions for a clinician or care team may include:
- Is this program appropriate for my pain condition, medication plan, and health history?
- Who delivers the sessions, and what training do they have in MORE or related clinical methods?
- How will opioid use, pain, craving, mood, and safety be monitored during the program?
- What should I do if symptoms worsen, cravings increase, or medication concerns arise?
- How does this fit with existing medical, behavioral health, or recovery support?
For people affected by opioid misuse, the safest next step is a conversation with a qualified healthcare professional. Research can clarify options and raise better questions, but personal medical decisions require professional assessment, especially where opioids, chronic pain, mental health, or substance use risks are involved.